Share
Copied
In recent years, more international tech companies, including pharmaceutical corporations, have been keen to establish their presence in China and seek more technological collaborations.
Novo Nordisk, a global pharmaceutical company specializing in treating diabetes and other chronic diseases, has been operating a research center in China for over 25 years. It has seen fruitful results through collaborations with Chinese research institutes, local biotech companies, and hospitals, according to Han Dan, president of Novo Nordisk Research Center China.
"Along the years, we have evaluated more than a hundred collaboration opportunities and has established more than 30 collaborations. And two of them has been matured into our pipeline to be pipeline projects," Han told CGTN in an interview on the sidelines of the Zhongguancun Forum, one of China's most high-level forums for science and technology.
These projects were incubated on the INNOVO platform that the center initiated in 2019. Going forward, Novo Nordisk Research Center China wishes to establish more collaboration with external communities.
"By 2025, we hope that 50 percent of our research projects comes from external collaborations," said Han.
Search Trends
SITEMAP
Copyright © 2023 CGTN. 京ICP备16065310号
Disinformation report hotline: 010-85061466
SITEMAP
Copyright © 2023 CGTN. 京ICP备16065310号
Disinformation report hotline: 010-85061466